Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

BMC Cancer

Table 3 Odds ratios for breast cancer by dose, frequency, and duration of exposure to celecoxib, rofecoxib, aspirin, and ibuprofen.

Compound^a	Dose	Frequency of Use	Multivariate OR^b(95% CI)
Celecoxib	200 mg	Daily	0.17 (0.03–0.83)
Rofecoxib	25 mg	Daily	0.36 (0.14–0.91)
Aspirin	325 mg	2–3 weekly	1.02 (0.30–3.57)
		>3 weekly	0.39 (0.22–0.72)
			trend (p < 0.05)
Ibuprofen	200 mg	2–3 weekly	0.59 (0.21–1.67)
		>3 weekly	0.28 (0.13–0.61)
			trend (p < 0.01)

^aMinimum duration of exposure: 2 years for celecoxib or rofecoxib, 5 years for aspirin or ibuprofen.
^bMultivariate odds ratios are adjusted for continuous variables (age and body mass) and categorical variables (parity, menopausal status, family history, smoking, and alcohol intake).

ISSN: 1471-2407